Impro: Share price of U.S. peer up nearly 300% in three years. Impro issues positive profit alert with extremely low comparable valuation ACN Newswire

Impro: Share price of U.S. peer up nearly 300% in three years. Impro issues positive profit alert with extremely low comparable valuation

HONG KONG, Jan 16, 2023 - (ACN Newswire via SEAPRWire.com) - The latest macro data published by the U.S. is not ideal. The market expects the Fed will continue to raise interest rates through to the end of 2023. By then, the federal funds rate may reach 4.9% and the higher interest rate level will once again trigger market concerns about asset price revaluation. It is clear that US stocks have been under pressure recently. U.S. peer Howmet's share price has risen by over 300% in the last three yearsFor well-managed companies, there is never a shortage of capital and opportunity in the capital market. The stock price of Howmet Aerospace (US stock code: HWM) has been on an upward trajectory, hitting new all-time highs. It has increased from a low of US$9.87 in May 2020 to a closing price of US$40.55 on 10 January this year, representing a surge of close to 300% in three years and nearly 30% in the last six months. Howmet is a global leader in engineered metal castings and precision machining products. It is the second largest in the industry in terms of investment casting sales (the market leader is Precision Castparts Corp., which Warren Buffett took private in 2015) with a current market capitalization of US$16.8 billion. Its price-to-earning (P/E) ratio is estimated at 38.6 times, and its price-to-book (P/B) ratio and price-to-sales (P/S) ratio is 5.1 times and 3.0 times, respectively.Impro's valuation is extremely low compared with HowmetImpro (01286.HK) is a company listed on the Hong Kong capital market and is engaged in the same investment casting business as Howmet. It is a world-leading manufacturer of high-precision, high-complexity and mission-critical casting and machined components, and the sixth largest investment casting manufacturer in the world and the largest in China. Compared with Howmet, Impro's current market capitalization is only US$620 million (HK$4.9 billion), with a P/E ratio of approximately 8 times, a P/B ratio of 1.1 times and a P/S ratio of 0.9 time. It is evident that the Company is significantly undervalued.Impro Precision issues positive profit alert Results is set for further growth As one of the world's top ten manufacturers of high-precision castings and machined components, Impro Precision is underestimated and has huge scope for further growth. The Company recently issued a positive profit alert. Its sales revenue for 2022 is expected to increase by 15% to HK$4.35 billion, with net profit of HK$550-600 million, a year-on-year increase of 43-56%. Like Howmet, Impro Precision has also benefited from the recovery of its aerospace business after the pandemic. With the market for aircraft parts in short supply, the Company's future performance has great potential. Despite the Company's record net profit and sales revenue, its share price closed at only HK$2.65, still below its all-time high and in the bottom range. Compared with the historical high of HK$5.20, there is still considerable room for upward movement.Leading stock in high-precision parts industry in Hong Kong Aerospace and Hydraulics businesses will become its new growth engineAs one of the few leading high-precision component companies in the Hong Kong stock market, with strong economies of scale, the Company's sales exceeded HK$4.3 billion in 2022, and it has established a global presence. To date, the Company has 21 plants, 10 sales offices and eight logistics and warehousing centers in North America, Europe and Asia. It also completed the acquisition of Foshan Ameriforge at a consideration of nearly RMB59 million and the hydraulic orbital motor business of Danfoss Power Solutions (Jiangsu) Co., Ltd., a subsidiary of Danfoss Group, for EUR65 million, on 15 August and 31 October 2022, respectively, to strengthen the Company's presence in the aerospace and hydraulics industries.One of the revaluation targets under a valuation system with Chinese characteristicsOn 21 November 2022, at the Annual Conference of Financial Street Forum 2022, Yi Huiman, Chairman of the China Securities Regulatory Commission, speaking on the structure and valuation of listed companies, said that there was a need to explore ways to build a valuation system with Chinese characteristics, so as to promote better functioning of the market's resource allocation.Obviously, the regulator has clearly recognized that it is very unreasonable for a number of listed companies, including Hong Kong stocks and A-shares, to be extremely undervalued by the market. The regulator has pointed out that it is necessary to conduct an in-depth study on the application scenarios of valuation theories in mature markets and grasp the valuation logic of different types of listed companies. It is believed that the signal from the regulator to explore the establishment of a valuation system with Chinese characteristics will be gradually developed and implemented at the level of investment banks and institutional investors. Compared with overseas benchmarking companies, the valuation of Impro is extremely unreasonable. The history of the development of the US stock market shows that a reasonable revaluation of the value of a listed company may be late, but it is never missed.Moreover, the market capitalization of Impro will soon exceed HK$5 billion, and it is likely to be included in the Shenzhen-Hong Kong Stock Connect and Shanghai-Hong Kong Stock Connect in the second half of this year, giving mainland investors the opportunity to invest in Impro. As a rare leader in the high-precision components industry, the Company has maintained continuous growth in its business performance. It is believed that, under the catalyst of multiple factors, Impro will move further along the new capital market curve. Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024 JCN Newswire

Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024

NEW YORK, NY, Jan 16, 2023 - (JCN Newswire via SEAPRWire.com) - PCG Digital -- Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company, is on track to deliver a safe and effective front-line treatment to a community of patients living with a rare, chronic cancer.[Image: Soligenix, Inc.]Cutaneous T-cell lymphoma (CTCL) is difficult to treat and remains an area of significant unmet medical need, with a very limited number of safe treatment options available. Soligenix estimates the potential worldwide market for its therapeutic, HyBryte(TM)(synthetic hypericin), to be in excess of $250 million for the treatment of CTCL.Soligenix accomplished a number of key milestones in 2022, but difficult global market conditions meant the company was unable to achieve the stock price gains it had hoped for.Soligenix has announced its intention to seek shareholder approval for a reverse stock split next month.Watch the video interview with Soligenix President and Chief Executive Officer, Dr. Christopher Schaber on Jan 12 to hear more: https://youtu.be/YLh2M_8DsUE.Q: Why did you decide a reverse stock split was the best course of action for Soligenix, and why now?A: The primary goal of a reverse stock split will be to maintain Soligenix's Nasdaq listing. As we wait for a potential NDA approval from the FDA, and work towards the US launch of HyBryte, it is a critical time to remain a Nasdaq listed company.A reverse stock split may also serve to increase the trading price of our common stock, making Soligenix a more attractive value proposition to a broader range of investors, including institutional investors. It also has the potential to support any future capital-raising efforts.We were in discussions with Nasdaq during 2022 to request additional time to regain compliance and did not take pursuit of this action lightly. We waited as long as we could to ensure we had time to announce all of our key milestones during the year, most notably the submission of our new drug application (NDA) for HyBryte(TM) in the treatment of CTCL, which has a global market potential of approximately $250 million.Q: How will remaining on the Nasdaq create opportunities for Soligenix shareholders?A: We see significant potential upside for Soligenix's shareholders. Increasing our trading price will, we believe, encourage new investor interest in Soligenix, potentially resulting in greater liquidity for our shareholders. Institutions are often reluctant to buy stocks with a price below a certain threshold, and a higher share price would increase Soligenix's marketability, trading volume and liquidity of our common stock. Similarly, we may see renewed interest from analysts and brokers that typically avoid following or recommending companies with low stock prices.Our Board of Directors has thoroughly reviewed Soligenix's position and options and has approved the reverse stock split as being in the company's best interests.Q: Soligenix has indicated it is expecting to achieve some significant milestones in 2023. Can you expand on that?A: Soligenix is expecting to achieve a number of important milestones in 2023. We are anticipating the FDA's acceptance of our NDA for review in the first half of the year, and later in the year, the potential NDA approval in the US of HyBryte.In Q4 2022, Soligenix was invited by the Biomedical Advanced Research and Development Authority (BARDA) to submit a full contract proposal for the development of single-vial, adjuvanted, heat stable subunit vaccines to prevent filovirus infection. We are expecting to hear from BARDA about this potential multi-year, multi-million dollar contract award for our vaccine candidates, SuVax(TM) and MarVax(TM), against Ebola and Marburg viruses.Also, in Q4 2022, Soligenix initiated a Phase 2 clinical trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis. We are excited to expand synthetic hypericin's development into different cutaneous T-cell diseases such as psoriasis, as we execute on our long-term strategy to enhance the value of this unique compound. Psoriasis is a widespread unmet medical need, affecting as many as 7.5 million people in the U.S. and between 60 and 125 million people worldwide. We expect to report results from the study in the second half of 2023.Q: Following FDA approval, what will be next for HyBryte?A: Our NDA for HyBryte has been granted FDA orphan drug and fast track designations, due to its potential as a safe and effective front-line treatment for CTCL. We are anticipating potential approval in the second half of 2023 and we are targeting the first quarter of 2024 for our US launch.Additionally, we announced in September 2022 that the FDA had awarded a $2.6 million Orphan Products Development grant for an expanded study of HyBryte(TM) in the treatment of CTCL, including in the home use setting. The home use setting is a very important growth area for us, so we are very excited that this investigator-initiated study will begin in the first half of this year.Our goal remains to deliver an innovative first-in-class therapy to the CTCL community, and we believe we are on track to achieve this important goal.For further information regarding Soligenix, Inc., please visit the Company's website at www.soligenix.com, subscribe to the YouTube channel @Soligenix, and follow on LinkedIn and Twitter at Soligenix_Inc.- YouTube: https://www.youtube.com/@SoligenixInc- LinkedIn: https://www.linkedin.com/company/soligenix-inc-/- Twitter: https://twitter.com/Soligenix_IncPCG DigitalE: info@pcgadvisory.comT: +1-646-863-6341DisclaimerThis communication was produced by PCG Digital Holdings, LLC, an affiliate of PCG Advisory Inc., (together "PCG"). PCG is not a registered or licensed broker-dealer nor investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. PCG may be compensated by respective clients for publicizing information relating to its client's securities. See www.pcgadvisory.com/disclosures. Copyright 2023 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Champion REIT Partners with St. James’ Settlement in Summer Movie Screening for SEN Children ACN Newswire

Champion REIT Partners with St. James’ Settlement in Summer Movie Screening for SEN Children

HONG KONG, Aug 22, 2022 - (ACN Newswire via SEAPRWire.com) - Champion Real Estate Investment Trust ("Champion REIT" or the "Trust") (Stock Code: 2778), owner of Three Garden Road and Langham Place, partnered with St. James' Settlement again this year to hold a movie screening of Doraemon: Nobita's Little Star Wars at Cinema City, Langham Place Mall. The event targeted underprivileged families living in Tin Shui Wai and their children with special educational needs (SEN), including autism, attention deficit hyperactivity disorder (ADHD), etc. Volunteers from Champion REIT enjoy watching the movie Doraemon: Nobita's Little Star Wars with the family beneficiariesVolunteers from Champion REIT promote diversity and inclusion in the communityFollowing the success of last year's Women Empowerment Programme - Champion Mothers, the event not only marked the Trust's continued collaboration with St. James' Settlement, but also provided a volunteering opportunity for staff members and their families to present gifts to the children, promoting social diversity and inclusion whilst sharing an enjoyable summer experience.The Trust has never forgotten its philosophy of giving back to society. It remains committed to working with non-profit organisations to create shared values and provide assistance to those in need in the community.About Champion REIT (Stock Code: 2778)Champion Real Estate Investment Trust is a trust formed to own and invest in income producing office and retail properties. The Trust focuses on Grade A commercial properties in prime locations. It currently offers investors direct exposure to nearly 3 million sq. ft. of prime office and retail floor area. These include two Hong Kong landmark properties, Three Garden Road and Langham Place, as well as joint venture stake in 66 Shoe Lane in Central London. Since 2015, the Trust has been included in the Constituent of Hang Seng Corporate Sustainability Benchmark Index of Hang Seng Indexes.Website: www.championreit.com For press inquiries:Strategic Financial Relations LimitedVicky Lee Tel: 2864 4834 Email: vicky.lee@sprg.com.hkChristina Cheuk Tel: 2114 4979 Email: christina.cheuk@sprg.com.hkYvonne Lee Tel: 2864 4847 Email: yvonne.lee@sprg.com.hk Website: www.sprg.com.hk Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
China-Euro Stock Connect Launch to a Flying Start, Gotion High-Tech GDR is officially listed on the SIX Swiss Exchange ACN Newswire

China-Euro Stock Connect Launch to a Flying Start, Gotion High-Tech GDR is officially listed on the SIX Swiss Exchange

HONG KONG, Aug 1, 2022 - (ACN Newswire via SEAPRWire.com) - At 9:00 p.m. on July 28, Beijing time and 3:00 p.m. on July 28, Swiss time, Gotion High-Tech's GDRs were successfully listed on the SIX Swiss Exchange with the sound of six crisp bells. The Chinese Ambassador to Switzerland, Wang Shiting, Swiss SIX Group Executive Board of Directors and head of the Global Exchange Tom Zeeb, and deputy general manager of the Shenzhen Stock Exchange, Tang Rui, delivered a speech and witnessed.Mr. LI Chen, Vice President and Secretary of the Strategic Capital Section of International Business Section, and Mr. PAN Wang rang the bell on behalf of the Company at the SZSE and SZSE simultaneously.President of Engineering R&D InstituteMr. WANG Qisui, President of China Business SectionOn 7.28, the listing ceremony of the first batch of GDRs for the China-Switzerland Stock Connect was held simultaneously on the SIX Swiss Exchange, the Shenzhen Stock Exchange and the Shanghai Stock Exchange. The listed companies by issuing GDRs at the SIX Swiss Exchang include Gotion High-Tech, GEM, Shanshan and Keda Manufacturing. Among them, Gotion High-Tech is the company with the largest GDR basic issuance scale at the Swiss Stock Exchange since the implementation of the China-Euro Connect and is the only Chinese company providing new energy solutions including electric vehicle (EV) batteries and energy storage systems (ESS) batteries that have been successfully listed in Switzerland so far. Mr. CAI Yi, Senior Vice President of Gotion High-Tech and President of ITRI, and Mr. WANG Qisui, President of China Business Section, delivered speeches on behalf of the Company at the SSE and SZSE respectively.Mr. CAI Yi stated in his full English speech that the successful listing of Gotion High-Tech's GDRs is a milestone in the Company's internationalization process. We will continue to expand our production capacity around the world, continue to invest in research and development to ensure our leading position in battery technology, continue to maximize shareholder value, continue to contribute to society and support the families of our employees around the world. In his speech, Mr. WANG Qisui said that the development of Gotion High-Tech is inseparable from the support of the government, the progress of Gotion High-Tech is inseparable from the opportunities of the industry, the growth of Gotion High-Tech is inseparable from its own efforts, and the future of Gotion High-Tech is inseparable from its compliance with international rules. "The successful issuance of our GDRs represents the recognition of the industry by domestic and foreign investors, and the recognition of Gotion High-tech not only shows the determination of the Chinese government to support the development of the new energy industry but also shows the confidence of Chinese enterprises to enter the international markets. It refreshes the world's understanding of the energy revolution."According to information from the Shenzhen Stock Exchange, with the approval of the China Securities Regulatory Commission, Gotion High-Tech has been listed at the Swiss Stock Exchange on July 28. It is the project with the largest issuance scale and the smallest discount among the first batch of Swiss GDR issuance projects. The number of Gotion High-Tech's GDRs placed amounted to 22,833,400 shares, accounting for 6.4% of the total equity interest after the issuance of GDRs; the offer price was US$30.00 (the offer price represented a discount of 3.5% on the previous closing price), and the gross proceeds of the GDRs were about US$685 million. After the listing of Gotion High-Tech's GDRs, the market performance was stable. On the first day of listing, the closing price was US$30, which was the same as the offer price. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More